PECAM1 and renal cell carcinoma: The significantly reduced CD31 positive vessels, CD31 protein and mRNA expression, and hemoglobin concentration suggest that Lm-LLO-CD105A effectively targets RCC-associated vasculature, contributing to its therapeutic efficacy.